Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 120 participants.
Also called NCT01969318
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 120 participants
- Registry
-
NCT01969318
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01969318. Randomized; quadruple masking; primary purpose prevention. Start 2012-03 (registry gives no type); primary completion 2012-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Placebo /Metformin
- Intervention (Drug)
- SP2086(50 mg q.d.)/Metformin
- Intervention (Drug)
- SP2086 (100 mg q.d.)/Metformin
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Record details
- Record id
cardio:ct-nct01969318- Content hash
71d3ccfb4f65ab7709350825040bde0afa81bdaab398a63737a782a761d82459